Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9574986 | 1.00 | LMNA (0.49) | LMNANPSR1CRHBPCRHR2CYP2D6 | |
| SCHEMBL7890911 | 1.00 | LMNA (0.49) | LMNANPSR1CRHBPCRHR2CYP2D6 | |
| SCHEMBL7316408 | 0.84 | LMNA (0.50) | LMNANPSR1CRHBPCRHR2TSHR | |
| SCHEMBL2481352 | 0.83 | APAF1 (0.55) | LMNACYP2D6SRCMMEAPAF1 | |
| SCHEMBL6155794 | 0.83 | APAF1 (0.55) | LMNACYP2D6SRCMMEAPAF1 | |
| SCHEMBL6809827 | 0.83 | APAF1 (0.55) | LMNACYP2D6SRCMMEAPAF1 | |
| SCHEMBL3823989 | 0.83 | APAF1 (0.55) | LMNACYP2D6SRCMMEAPAF1 | |
| SCHEMBL18722284 | 0.83 | APAF1 (0.55) | LMNACYP2D6SRCMMEAPAF1 | |
| SCHEMBL4679414 | 0.82 | KMT2A (0.58) | LMNANPSR1CRHBPCRHR2MAPK1 | |
| Hydrochloric Acid SCHEMBL21333388 | 0.82 | MME (0.54) | LMNACYP2D6SRCMMEAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-3997105-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Protagonist Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2021146454-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021146458-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| EP-3820883-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Protagonist Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| WO-2021007433-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| EP-3169403-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | Protagonist Therapeutics Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016011208-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| EP-0592511-B1 | SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS | ANTIVIRALS INC (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0669927-A1 | SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS | ANTIVIRALS INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| US-5405938-A | Hydrogen bonding an N-heterocyclic-substituted ribose-based polymer to a double-stranded DNA to block genetic activity, to diagnose for pathogens and to aid in genetic engineering | ANTI-GENE DEVELOPMENT GROUP (US) | 1995-04-11 | — | — | US | disclosed |
| WO-1994012517-A1 | SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS | ANTIVIRALS INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| EP-0592511-A1 | SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS. | ANTIVIRALS INC (US) | 1994-04-20 | — | — | EP | disclosed |
| EP-0528172-A1 | (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1993-02-24 | — | — | EP | disclosed |
| WO-1993000352-A1 | SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS | ANTIVIRALS INC. (US) | 1993-01-07 | — | — | WO | disclosed |
| US-5166315-A | Polynucleotides for genetic engineering | ANTI-GENE DEVELOPMENT GROUP (US) | 1992-11-24 | — | — | US | disclosed |